The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The added value of early detection and interception in patients with myeloma
In this video, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the benefit of early detection and interception in patients with multiple myeloma. Dr Ghobrial explains the importance of screening for precursor conditions, and further emphasizes the benefit of treating at the smoldering myeloma stage. Following this, Dr Ghobrial highlights the benefit of precision interception and the added value of using immunotherapy at an earlier stage. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Irene Ghobrial, MD, discloses links to Janssen, Sanofi, BMS, GSK, Karyopharm and Binding Site.
